Cargando…
Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study
INTRODUCTION: In this study, we evaluated the safety and pharmacodynamic effects of the Fc-inactivated anti-β-amyloid (anti-Aβ) monoclonal antibody GSK933776 in patients with mild Alzheimer’s disease and mild cognitive impairment. Aβ and tau levels were investigated in cerebrospinal fluid (CSF), and...
Autores principales: | Leyhe, Thomas, Andreasen, Niels, Simeoni, Monica, Reich, Arno, von Arnim, Christine AF, Tong, Xin, Yeo, Astrid, Khan, Shahid, Loercher, Amy, Chalker, Michelle, Hottenstein, Charles, Zetterberg, Henrik, Hilpert, Jan, Mistry, Prafull |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055052/ https://www.ncbi.nlm.nih.gov/pubmed/24716469 http://dx.doi.org/10.1186/alzrt249 |
Ejemplares similares
-
First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer’s Disease: A Randomized, Placebo-Controlled Study
por: Andreasen, Niels, et al.
Publicado: (2015) -
Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010) -
Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013) -
Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010) -
Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer’s Disease
por: Kirouac, Lisa, et al.
Publicado: (2017)